Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: May 19, 2011

Premium

Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Lung Cancer

Patent Number: 7,943,318

Filed: Jan. 3, 2007

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent's abstract states, “provides novel methods and compositions for the diagnosis, prognosis, and treatment of lung cancer. The invention also provide methods of identifying anti-lung-cancer agents.”


Title: siRNA Microbicides for Preventing and Treating Diseases

Patent Number: 7,943,589

Filed: June 5, 2006

Lead Inventor: Judy Lieberman, Immune Disease Institute (Harvard University)

“The invention provides a microbicidal composition comprising at least one siRNA,” the patent's abstract states. “The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2.

“The microbicidal composition further comprises a pharmaceutically acceptable carrier,” the abstract adds. “Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.”


Title: RNAi Inhibition of Alpha-ENaC Expression

Patent Number: 7,943,592

Filed: April 30, 2010

Lead Inventor: Gino Van Heeke, Novartis

“The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the down-regulation of alpha-ENaC expression by chemically modified oligonucleotides,” the patent's abstract states.


Title: Bioinformatically Detectable Group of Novel Regulatory Bacterial and Bacterial-Associated Oligonucleotides and Uses Thereof

Patent Number: 7,943,754

Filed: May 24, 2004

Lead Inventor: Isaac Bentwich, Rosetta Genomics

The invention, the patent's abstract states, relates to a group of “novel bacterial- and human-associated oligonucleotides, here identified as Genomic Address Messenger or GAM [oligonucleotides and a group] of novel operon-like bacterial and human polynucleotides, here identified as Genomic Record or GR [polynucleotides].

“GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various bacterial infections,” the abstract states. “Nucleic acid molecules are provided respectively encoding 21,916 bacterial and 6,100 human GAM precursor oligonucleotides, and 6,056 bacterial and 430 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides, and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.”


Title: Anti-microRNA Oligonucleotide Molecules

Patent Number: 7,943,756

Filed: June 4, 2010

Lead Inventor: Thomas Tuschl, Rockefeller University

“The invention relates to isolated anti-microRNA molecules,” according to the patent's abstract. “In another embodiment, the invention relates to an isolated microRNA molecule. In yet another embodiment, the invention provides a method for inhibiting microRNP activity in a cell.”


Title: RNA Interference-Mediated Inhibition of Intracellular Adhesion Molecule Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,943,757

Filed: July 16, 2010

Lead Inventor: James McSwiggen, Merck

“This invention relates to compounds, compositions, and methods useful for modulating intercellular adhesion molecule gene expression using short interfering nucleic acid molecules,” the patent's abstract states. “This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ICAM gene expression and/or activity by RNA interference using small nucleic acid molecules.”


Title: Modulation of LDL Receptor Gene Expression with Double-Stranded RNAs Targeting the LDL Receptor Gene Promoter

Application Number: 20110110860

Filed: Nov. 2, 2010

Lead Inventor: David Corey, University of Texas (Alnylam Pharmaceuticals)

“Gene expression can be selectively regulated by double-stranded antigene RNAs that target regions of the low density lipoprotein receptor promoter, thereby permitting modulation of LDL levels in vivo and subsequent effects on circulating LDL levels,” the patent application's abstract states.


Title: Composition and Method for Introduction of RNA Interference Sequences into Targeted Cells and Tissues

Application Number: 20110110937

Filed: Nov. 1, 2010

Inventor: Michael Simon, Henry Ford Health System

“A composition and method are provided by which double-stranded RNA containing small interfering RNA nucleotide sequences is introduced into specific cells and tissues for the purpose of inhibiting gene expression and protein production in those cells and tissues,” the patent application's abstract states. “Intracellular introduction of the small interfering RNA nucleotide sequences is accomplished by the internalization of a target-cell-specific ligand bonded to a RNA binding protein to which a double-stranded RNA containing a small interfering RNA nucleotide sequence is adsorbed. The ligand is specific to a unique target cell surface antigen. The ligand is internalized after binding to the cell surface antigen or by the incorporation of a peptide into the structure of the ligand or RNA binding protein or attachment of such a peptide to the ligand or RNA binding protein. The composition and method are practiced in whole living mammals, as well as cells living in tissue culture.”


Title: Bacterially Derived Intact Minicells that Encompass Plasmid-Free Functional Nucleic Acid for In Vivo Delivery to Mammalian Cells

Application Number: 20110111041

Filed: Dec. 29, 2010

Lead Inventor: Himanshu Brahmbhatt, Engeneic Therapy

“Intact, bacterially derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells,” the patent application's abstract states. “To this end, functional nucleic acid can be packaged into intact minicells directly, without resorting to expression constructs, the expression machinery of the host cell, harsh chemicals, or electroporation.”


Title: Nanoparticle Compositions for Nucleic Acids Delivery System

Application Number: 20110111044

Filed: July 31, 2009

Lead Inventor: Hong Zhao, Enzon Pharmaceuticals

The invention, the patent application's abstract states, “is directed to nanoparticle compositions for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to oligonucleotides encapsulated in a mixture of a cationic lipid, a fusogenic lipid, and a PEG lipid.”


Title: Peptide Dicer-Substrate Agents and Methods for Their Specific Inhibition of Gene Expression

Application Number: 20110111056

Filed: June 3, 2010

Lead Inventor: Sujit Basu, Dicerna Pharmaceuticals

“This invention relates to compounds, compositions, and methods useful for reducing a target RNA and protein levels via use of Dicer-substrate siRNA-peptide conjugates,” the patent application's abstract states.


Title: Compositions and Methods for Nucleic Acid Delivery

Application Number: 20110111459

Filed: April 20, 2009

Inventor: Frederick Boyce, Massachusetts General Hospital

The invention, the patent application's abstract states, comprises “methods and compositions for preparing a lipid-encapsulated nucleocapsid delivery composition capable of delivering a nucleic acid to a mammalian cell. The nucleocapsid delivery compositions disclosed herein are useful for large-scale protein production, expression of genes in a mammalian expression system, and/or pharmaceutical production of a recombinant protein for treatment of an individual. In addition, the nucleocapsid delivery compositions can be used to treat an individual to replace a gene or gene product, or alternatively to inhibit a gene product using an RNA interference molecule.”


Title: Enabling the Use of Long dsRNA for Gene Targeting in Mammalian and Other Selected Animal Cells

Application Number: 20110111481

Filed: June 30, 2008

Inventor: Chiang Li, Beth Israel Deaconess Medical Center

The invention “provides a method of enabling the use of long dsRNA for gene silencing in mammalian cells through bacteria, preferably non-pathogenic or therapeutic strains of bacteria,” the patent application's abstract states. “DNA that encodes long double-strand RNAs are transformed into bacteria and processed in the bacterial cells into a mixture of smaller RNA duplexes and then released into the cytoplasm of the target cells, resulting in modulation of gene expression in the target cells. The methods overcome the incompatibility between long strong dsRNA and mammalian cells by eliminating, or mitigating, the non-specific innate immune response. The eukaryotic cells can be mammalian cells or avian cells. The gene of interest can be a mammalian, avian, bacterial, eukaryotic, or viral gene.”


Title: RNA Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof

Application Number: 20110111491

Filed: May 5, 2010

Lead Inventor: Beverly Davidson, University of Iowa

The invention comprises “small interfering RNA molecules targeted against nucleic acid sequence that encodes huntingtin or ataxin-1, and methods of using these siRNA molecules,” the patent application's abstract states.


Title: Compositions and Methods for Inhibiting Expression of a Target Gene

Application Number: 20110111493

Filed: Sept. 29, 2010

Lead Inventor: Roland Kreutzer, Alnylam Pharmaceuticals (Roche)

The invention, the patent application's abstract states, “relates to a double-stranded ribonucleic acid having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary RNA strand having a [one-to-four] nucleotide overhang at the 3'-end and a blunt 5'-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages. The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.”


Title: Bacteria-Mediated Gene Modulation Via microRNA Machinery

Application Number: 20110111496

Filed: June 30, 2008

Inventor: Chiang Li, Beth Israel Deaconess Medical Center

The invention “provides a method of synthesizing, processing, and/or delivering miRNA or its precursors to eukaryotic cells using bacteria, preferably non-pathogenic or therapeutic strains of bacteria, to effect gene modulation in eukaryotic cells,” the patent application's abstract states.


Title: Complex of Polysaccharide and Double-Stranded RNA

Application Number: 20110111501

Filed: Dec. 18, 2008

Lead Inventor: Takanori Kubo, National Institute of Advanced Industrial Science and Technology

The invention, the patent application's abstract states, comprises “novel double-stranded RNA having an RNA interference effect, in which the cellular uptake and the resistance to enzymatic degradation are improved, without reducing the RNA interference effect. The cellular uptake and the resistance to enzymatic degradation of a complex of a polysaccharide having a beta-1,3-glucan skeleton and double-stranded RNA can be significantly improved while maintaining the RNA interference effect.”


Title: microRNA Biomarkers of Tissue Injury

Application Number: 20110111976

Filed: April 24, 2009

Lead Inventor: Thomas Fare, Merck

“The invention generally relates to use of tissue-enriched miRNAs as [biomarkers] to estimate tissue damage in a fluid sample,” the patent application's abstract states. “Methods are provided for monitoring a subject who is exposed or might have been exposed to an agent that has a risk of causing tissue injury … [as are methods] for identifying an agent as having a risk of causing tissue injury to a vertebrate subject … [and kits] for practicing the methods of above-listed aspects.”


Title: siRNA Targeting Spleen Tyrosine Kinase

Application Number: 20110111983

Filed: Dec. 6, 2010

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes.”


Title: Novel siRNA Structures

Application Number: 20110112168

Filed: Sept. 4, 2008

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

“The invention relates to siRNA compounds possessing novel sequences and structural motifs which down-regulate the expression of specific human genes,” the patent application's abstract states. “The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The ... invention also provides a method of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions comprising administering to a subject in need of treatment for such disease or condition and/or symptom the compound or the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.”


Title: RNAi-Based Therapeutics for Allergic Rhinitis and Asthma

Application Number: 20110112169

Filed: Sept. 27, 2010

Lead Inventor: Jianchu Chen, Massachusetts Institute of Technology

The invention provides “compositions comprising one or more RNAi agents for the treatment of conditions and diseases … featuring IgE-mediated hypersensitivity, as well as systems for identifying RNAi agents effective for this purpose,” the patent application's abstract states. “The compositions are suitable for the treatment of allergic rhinitis and/or asthma.”


Title: Methods and Compositions Involving microRNA

Application Number: 20110112173

Filed: Sept. 24, 2010

Lead Inventor: David Brown, Asuragen

The invention, the patent application's abstract states, “concerns methods and compositions for isolating, enriching, and/or labeling miRNA molecules and for preparing and using arrays or other detection techniques for miRNA analysis. Moreover, the ... invention concerns methods and compositions for generating miRNA profiles and employing such profiles for therapeutic, diagnostic, and prognostic applications.”


Title: Compositions and Methods for Inhibiting Expression of IKK-B Gene

Application Number: 20110112178

Filed: Dec. 30, 2010

Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene,” the patent application's abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell.”


Title: RNA Interference-Mediating Small Molecules

Application Number: 20110112283

Filed: Oct, 4, 2010

Lead Inventor: Thomas Tuschl, Max Planck Institute

“Double-stranded RNA induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference,” the patent application's abstract states. “Using a Drosophila in vitro system, we demonstrate that 19 [to] 23 [nucleotide long] short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3' ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.”

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.